The next installment of our Meet the VCs webinar series, we’re pleased to have had Kyle Welborn of Cultivation Capital and Alex Bondar of Acre Venture Partners join us. Kyle will start us off with an overview of the 2025 AgTech area investment and exit data, observations on the various market sectors within AgTech, and…
To continue the conversation from an earlier webinar, Founding a Startup as Graduate Students, Shelley Force Aldred sat with us to answer some questions that were submitted during the webinar that we were unable to get to due to time.
Here is the first in a series of webinars to introduce you to VCs who often invest in startups arising from academic research. Our introductory “Meet the VCs” session will highlight Mission BioCapital and Portal Innovations, both of which are early-stage life science investors that also offer state-of-the-art shared lab facilities in multiple locations. Our…
This is part 1 of a 5-part webinar series called Startup Licensing 101: A Resource for Entrepreneurs Working with Companies Originated at Academic Institutions.
For many entrepreneurs, licensing from a university may be a new experience. This series of webinars provides information that will be helpful for academic entrepreneurs contemplating their first (or perhaps subsequent) license from an academic institution. Presented by an attorney who represents many academic startups, including their investors, along with two academic technology transfer veterans, these webinars bring views from both sides of the table and best practices for a fruitful and efficient negotiation.
Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?
We’re almost halfway through 2018, which means it is once again time for OUP’s annual financing trends webinar. Which sectors have had the greatest investment and which are facing funding challenges? How do these trends apply to advancing academic technologies? What does the beginning of 2018 imply for the rest of the year and what lies over the horizon?